financetom
Business
financetom
/
Business
/
Comscore beats Q2 revenue estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Comscore beats Q2 revenue estimates
Aug 5, 2025 1:23 PM

Overview

* Comscore ( SCOR ) Q2 revenue rises 4.1% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q2 beats estimates, up 25% yr/yr

* Net loss of $9.5 mln due to FX fluctuations, taxes, and interest

Outlook

* Comscore ( SCOR ) maintains full-year revenue and adjusted EBITDA guidance

* Company expects Q3 revenue to be flat year-over-year

* Comscore ( SCOR ) sees growth in local TV and cross-platform offerings

* Company anticipates declines in syndicated digital products

Result Drivers

* CROSS-PLATFORM GROWTH - 60% increase in cross-platform revenue driven by Proximic and content measurement offering

* LOCAL TV EXPANSION - Double-digit growth in local TV revenue due to key renewals and new business

* REVENUE DECLINE - Lower revenue from national TV and syndicated digital products

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $89.39 $85.90

Revenue mln mln (2

Analysts

)

Q2 EPS -$2.73

Q2 Net -$9.49

Income mln

Q2 Beat $8.90 $8.75

Adjusted mln mln (2

EBITDA Analysts

)

Q2 -$1.68

Income mln

from

Operatio

ns

Q2 -$7.04

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advertising & marketing peer group is "buy."

* Wall Street's median 12-month price target for Comscore Inc ( SCOR ) is $5.50, about 5.5% above its August 4 closing price of $5.20

* The stock recently traded at 1 times the next 12-month earnings vs. a P/E of 1 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alcoa's Q1 Adjusted Earnings Seen Topping Estimates, UBS Says
Alcoa's Q1 Adjusted Earnings Seen Topping Estimates, UBS Says
Mar 27, 2025
03:16 PM EDT, 03/27/2025 (MT Newswires) -- Alcoa's ( AA ) Q1 adjusted earnings probably will top Wall Street estimates amid a constructive outlook for aluminum, UBS AG London said Thursday in a report. UBS forecasts Q1 adjusted earnings of $1.74 a share versus the consensus of $1.44. Earnings before interest, taxes, depreciation and amortization of $805 million may exceed...
US beef sales to China skid after Beijing lets export registrations lapse
US beef sales to China skid after Beijing lets export registrations lapse
Mar 27, 2025
CHICAGO (Reuters) - U.S. beef sales to China have taken a dive, U.S. government data showed on Thursday, after Beijing allowed the expiration of registrations that had permitted exports from hundreds of American meat facilities. A tit-for-tat tariff dispute has also raised duties on U.S. meat and other goods shipped to China, making the products less attractive to Chinese buyers....
Suncor says it is responding to incident involving St. Clair River
Suncor says it is responding to incident involving St. Clair River
Mar 27, 2025
March 27 (Reuters) - Suncor Energy Inc ( SU ) on Thursday reported it was responding to an incident involving the St. Clair River near its 85,000-barrels-per-day refinery in Sarnia, Ontario, according to a community alert. St. Clair Township reported there has been a spill to St. Clair river that could result in unsafe water conditions. ...
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Mar 27, 2025
The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc. ( BBIO )‘s acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy, resulting in heart failure. AstraZeneca Plc...
Copyright 2023-2026 - www.financetom.com All Rights Reserved